Signaling by receptor activator of nuclear factor kB (RANK) in response to its ligand RANKL, which is a member of the tumor necrosis factor (TNF) superfamily of cytokines, stimulates osteoclast formation and bone resorption. Thus, this ligand-receptor pair is a therapeutic target for various disorders, such as osteoporosis and metastasis of cancer to bone. RANKL exists as a physiological homotrimer, with each monomer recognizing a single molecule of RANK or the decoy receptor osteoprotegerin (OPG), which inhibits osteoclastogenesis. We engineered a RANKL protein in which all three monomers of RANKL were encoded as a single polypeptide chain, which enabled us to independently control receptor binding at each binding interface. To generate an effective RANK inhibitor, we used an unbiased forward genetic approach to identify mutations in RANKL that had a 500-fold increased affinity for RANK but had decreased affinity for the decoy receptor OPG. Incorporating mutations that blocked receptor binding into this high-affinity RANKL variant generated a mutant RANKL that completely inhibited wild-type RANKL-induced osteoclastogenesis in vitro and bone resorption in mice. Our approach may be generalized to enable the inhibition of other TNF receptor signaling systems, which are implicated in a wide range of pathological conditions.
INTRODUCTION
Excessive activation of receptors for members of the tumor necrosis factor (TNF) superfamily of cytokines induces myriad pathological conditions (1, 2) . Whereas biological agents have had positive effects on the course of these diseases, each agent carries substantial complications (3) . The TNF superfamily member receptor activator of nuclear factor kB ligand (RANKL) is the key cytokine that stimulates the formation and activity of osteoclasts (4) (5) (6) (7) , and excess activation of its receptor RANK promotes many, if not most, forms of pathological bone loss. RANKL exists as a homotrimer in solution (8) , and each of the three interfaces separating the monomers contains a binding groove that accepts a single molecule of RANK or the anti-osteoclastogenic decoy receptor osteoprotegerin (OPG) (9) (10) (11) . The most common means of therapeutically inhibiting TNF receptor (TNFR) signaling is sequestration of the cytokine by a humanized monoclonal antibody. Similarly, the sole approved inhibitor of the RANKL pathway is the humanized monoclonal antibody denosumab, which targets the cytokine, but not its receptor, and its effects last for 7 to 9 months (12) . Given the profound suppression of bone remodeling that accompanies cytokine removal or other anti-bone-resorptive strategies, shorter-acting agents are needed. We herein report the generation of an inhibitor of RANKL-stimulated signaling that blocks RANK activation with a high-affinity mutant and fails to recognize OPG. The capacity to block one receptor of a given cytokine while sparing another suggests that the same strategy may be effective in regulating other TNF superfamily members.
RESULTS
We covalently linked three RANKL monomers with two short glycine-rich linkers (Fig. 1A ), which were modeled after previously reported singlechain versions of other TNF superfamily members (13) (14) (15) (16) . This version of RANKL encoded as a single-chain (scRANKL) protein enabled individual modification of the binding affinities of the three binding sites for RANK and OPG. We refer to the noncovalently linked, homotrimeric version of RANKL as "htRANKL." Two additional surface "solubility" mutations Cys 220 →Ser and Glu 246 →Ile (C220S/E246I), which do not affect the binding of the mutant RANKL to RANK or its function, were introduced to improve protein production (fig. S1, A and B). This version of RANKL is referred to as "WT-SM htRANKL." Therefore, all versions of htRANKL and scRANKL incorporate these two solubility mutations. As expected, no monomeric species of scRANKL was observable on a denaturing gel (Fig. 1B) , and scRANKL migrated similarly to the trimeric species of chemically cross-linked wild-type htRANKL. To avoid potential discrepancies in molecular mass when comparing the cross-linked protein to the native protein, we more precisely determined the molecular masses of htRANKL and scRANKL by multi-angle light scattering (MALS) analysis. We found that scRANKL had a molecular mass consistent with that of three covalently linked RANKL monomers ( fig. S2A ). Moreover, scRANKL induced bone marrow-derived macrophages (BMMs) to undergo osteoclastogenesis as effectively as did the wild-type cytokine (Fig. 1C and fig. S2B ).
To engineer scRANKL constructs that blocked receptor binding at one site ("single-block scRANKL") or two sites ("double-block scRANKL," Fig. 1D ), we inserted short sequences into several loops of RANKL ( Fig.  2A) or introduced point mutations that disrupted salt bridge formation ( fig. S3 ). One mutant, in which three amino acid residues (Gly-Gly-Ser) were inserted into the CD loop (CDins htRANKL), which includes amino acid residues 224 to 233, failed to bind to a recombinant fusion protein of Fc and RANK (RANK-Fc) despite undergoing proper folding, as established by its ability to bind to OPG-Fc in a dose-dependent manner (Fig. 2B) . Consistent with its failure to bind to RANK, the CDins htRANKL mutant was incapable of inducing osteoclast formation or promoting RANK signaling in BMMs (Fig. 2C) . Next, we generated single-block and doubleblock scRANKL mutants by inserting CDins into one or two monomers, respectively, of the single-chain trimer. We compared the degree of receptor binding at saturation by flowing monomeric RANK, as an analyte, over a surface plasmon resonance (SPR) chip. As expected, blocking each binding site diminished receptor recognition by about one-third (Fig. 2D) .
Having developed scRANKL variants that had an altered capacity to initiate trimeric receptor clustering, which is presumed to be required for optimal signaling, yet retained the ability to bind to RANK, we postulated that these proteins might act as inhibitors of osteoclastogenesis induced by wild-type htRANKL; however, this proved not to be the case ( fig. S4 ). This lack of inhibitory ability likely reflected the failure of the one (or two) intact binding site(s) to overcome the avidity afforded by the three sites of wild-type htRANKL. We reasoned that we might increase the inhibitory effectiveness by compensating for the reduced avidity of single-block or double-block scRANKL through increasing the affinity for RANK at the intact site(s). This required identifying previously uncharacterized RANKL mutations that increased its affinity for RANK. To this end, we performed two generations of in vitro affinity maturation through yeast surface display (YSD) (17) . The first round involved creating a library of htRANKL mutants through error-prone polymerase chain reaction (PCR) assays and sorting for clones that retained the ability to bind to RANK-Fc. Notably, OPG, the principal biological inhibitor of RANK-induced osteoclastogenesis (18) (19) (20) , exerts its effects by competing with RANK for binding to RANKL. Because both RANK and OPG bind to the same groove of RANKL, it is possible that increasing the affinity of RANKL for RANK could simultaneously increase its binding to the decoy receptor. To obviate this possibility, we simultaneously sorted the library for clones with higher affinity for RANK and with decreased affinity for OPG-Fc ( fig. S5A ). Reversion mutagenesis yielded individual point mutations (K194N, Q236H, and F269Y) in htRANKL that, when expressed in combination (KQF), substantially increased the affinity of the mutant htRANKL for RANK-Fc while decreasing its affinity for OPG-Fc ( fig. S5, B and C) .
In the second generation of in vitro evolution, we selected htRANKL variants with long kinetic half-lives for binding to RANK. We again constructed an htRANKL mutant library through error-prone PCR, but this time, we used the high-affinity KQF htRANKL mutant as a starting template. Because of its rapid off-rate, monomeric RANK did not stain yeast-displayed wild-type htRANKL, despite their established interaction (Fig. 3A) . We therefore sorted the second library with sequentially limiting amounts of monomeric RANK. This sorting strategy yielded a population of htRANKL variants that were capable of binding to monomeric RANK (Fig. 3A) . Next, we selected htRANKL variants that continued to bind to limiting amounts of RANK after incubation in the presence of unlabeled OPG for 5 min at room temperature ( fig. S6 ). We identified several additional mutations at residue K 194 and chose to use the K194E mutation going forward in KQF htRANKL because the K194N mutation introduced a potential N-linked glycosylation site that could confound results when comparing proteins produced by yeast and mammalian cells. These strategies also yielded the htRANKL point mutant (H270Y), which, when incorporated into the KQF htRANKL mutant, further increased its affinity for RANK without yielding detectable binding to OPG (Fig. 3B) .
We then determined the affinities and kinetic parameters of the RANKL variant that showed the greatest binding to RANK by SPR (Fig. 3C) . Although the two solubility mutations that were introduced to produce scRANKL had no effect on RANK binding, they resulted in an about 10-fold decrease in binding to OPG ( fig. S7 ). The KQFH htRANKL variant bound to RANK with an about 500-fold greater affinity than did wild-type htRANKL; however, it exhibited substantially impaired binding to OPG (Fig. 3B ). These changes in affinity for RANK largely reflected a prolonged half-life of binding, changing from a relatively rapid dissociation time (t 1/2 = 3 s for wild-type htRANKL) to a dissociation time that was more than 200 times longer (t 1/2 = 675 s for KQFH htRANKL). The KQFH mutations cluster in two regions of RANKL that were previously implicated in binding to RANK ( fig. S8) (9) . To ensure that the RANK-blocking interface would also block binding to OPG, we combined CDins with the Q236H mutation because Gln 236 was identified by YSD as the amino acid residue responsible for decreased binding to OPG. Indeed, we confirmed that the variant RANKL that combined CDins with the Q236H mutation did not bind to RANK ( fig. S9 ).
To generate an effective inhibitor of RANKL-mediated signaling, we incorporated the high-affinity KQFH variant (RANK high ) into our singleblock and double-block constructs (Fig. 4A) . Before determining the capacity of these scRANKL variants to act as inhibitors of RANKL-RANK signaling, we assessed their capacity to generate osteoclasts. Both the single-block and double-block scRANKL variants that had increased affinity for RANK (single-block, RANK high and double-block, RANK high ) were incapable of generating osteoclasts in vitro (Fig. 4B) . Concurrently, we observed a lack of associated signals induced by the single-block, RANK high variant (Fig. 4C) . In contrast to the failure of single-block or double-block scRANKL containing unaltered residual monomer(s) to inhibit RANK signaling and osteoclast formation, the double-block, RANK high scRANKL variant effectively inhibited signaling stimulated by wild-type htRANKL with a median inhibitory concentration (IC 50 ) of~10 nM (Fig. 4D ). The potency of inhibition increased (resulting in an IC 50 of 0.2 nM) when two sites were available to bind RANK with high affinity (single-block, RANK high ), and this effect was not attributable to cytotoxic effects (fig. S10A). Additionally, blockade was specific for RANK-mediated signaling because TNFR1-mediated phosphorylation of IkBa downstream of TNF-a was not blocked by the single-block, RANK high variant ( fig. S10B ). The inhibitory effects of the single-block, RANK high variant were not limited to exogenous wild-type htRANKL because it also dose-dependently inhibited osteoclast formation induced by htRANKL produced by osteoblasts (Fig. 4E) . Last, we sought to test the effectiveness of the single-block, RANK high variant at blocking recombinant wild-type htRANKL-induced osteoclastic bone resorption in vivo. Intraperitoneal injection of recombinant wild-type htRANKL into 8-week-old BALB/c mice increased osteoclast function as determined by measuring the serum concentration of C-terminal collagen cross-links (CTx), a marker of bone resorption (Fig.  4F ). This increase in bone resorption was completely abrogated by the addition of an equal amount of the single-block, RANK high variant, which suggests that this inhibitor may have therapeutic potential.
DISCUSSION
Our results suggest that scRANKL, consisting of a combination of blocked and high-affinity RANK-binding sites, inhibits RANK signaling, thus acting as an effective inhibitor of RANKL-mediated osteoclast formation and function. RANKL, a member of the TNF superfamily of cytokines, binds to multiple receptors (RANK and OPG) with different biological effects. Within this superfamily, there are several examples of cytokines that demonstrate promiscuity in receptor usage (21) . For example, TNF-a, which recognizes both TNFR1 and TNFR2, is central to the pathogenesis of disabling disorders, such as rheumatoid arthritis and psoriasis (22) . Indeed, treatment of these diseases has been greatly facilitated by systemic blockade of TNF-a with humanized antibodies or soluble receptor (23, 24) . As effective as these drugs are, however, they cause major complications, such as a predisposition to malignancy and serious infections, including tuberculosis (25, 26) . Current evidence indicates that the positive effects of anti-TNF-a therapy reflects suppressed activation of TNFR1, whereas the negative consequences are a result of inhibition of the pro-immune properties of TNFR2 (27, 28) . TNF and RANKL interact with their receptors in a homologous fashion (9, 10, 29, 30) . Our data suggest that the strategy of combining high-affinity mutations and blocking mutations into a single chain can be used to construct an effective inhibitor that is receptor-selective. This suggests a potential mechanism for blocking TNFR1 stimulation while sparing TNFR2, thereby reducing systemic complications. In principle, a covalently linked system offers an advantage over the use of mixed heterotrimers (31) in that the composition of each receptor-binding interface is predetermined. Indeed, this strategy may be broadly applicable to all members of the pathologically important TNF superfamily.
MATERIALS AND METHODS
Construction of an scRANKL vector and cloning of complementary DNAs encoding scRANKL, htRANKL, and TNF-a into a mammalian expression vector Initially, the complementary DNA (cDNA) encoding scRANKL was cloned into the pGEX vector (GE Healthcare) by PCR-based amplification of the coding sequence of the mouse RANKL monomer (including amino acid residues 162 to 316 of National Center for Biotechnology Information Reference Sequence NP_035743) with primer pairs that inserted the following restriction enzyme sites: 5′-Sma I-RANKL-Bsp EI-3′, 5′-Bsp EI-RANKL-Bam HI-3′, and 5′-Bam HI-RANKL-Not I-3′. The primers were designed such that the three monomers are separated by a linker sequence [(Gly-GlySer-Gly) × 3]. Each insert was double-digested with the appropriate restriction enzymes (Fermentas) and ligated into the pGEX vector between the Sma I and Not I sites. The entire scRANKL cDNA was subcloned into the mammalian protein expression vector pFM (32) (gift of F. Mancia) downstream of the signal peptide from pHLsec (MGILPSPGMPALLSLVSLLSVLLMGCVA) (33) . To aid protein recovery, a tobacco etch virus (TEV) protease cleavage site and a 6xhistidine (6xHis) tag were added at the C terminus (SSGRENLYFQGHHHHHH). In brief, the construct encodes the following: a signal peptide, RANKL (residues 162 to 316), a linker, RANKL (residues 162 to 316), a linker, RANKL (residues 162 to 316), a TEV cleavage site, and the 6xHis tag. Expression of the construct is driven by the cytomegalovirus (CMV) promoter. Transfection efficiency was monitored by detection of red fluorescent protein, whose expression is initiated downstream of scRANKL at an internal ribosomal entry site. To clone the cDNA encoding htRANKL into the pFM mammalian expression vector, the cDNA sequence encoding amino acid residues 162 to 316 was amplified, digested with the restriction enzymes Bsu 36I and Sal I, and ligated downstream of the pHLsec signal peptide and upstream of the TEV cleavage site. To clone the cDNA encoding murine TNF-a, the cDNA sequence encoding amino acid residues 90 to 325 was amplified by overlap extension PCR to add a 5′ pHLsec signal peptide site and a 3′ Sal I restriction site. The cDNAwas digested with Xba I and Sal I and ligated downstream of the CMV promoter and upstream of the TEV cleavage site.
Production of mammalian RANKL and TNF-a proteins
Suspension-adapted FreeStyle 293 cells (Life Technologies) were maintained in serum-free FreeStyle 293 expression medium (Life Technologies) according to the manufacturer's protocol. For transfection, DNA was prepared with an endotoxin-free maxiprep kit (Qiagen). Cells were seeded at a density of 0.5 × 10 6 /ml in 200 ml of medium 24 hours before transfection. On the day of transfection, DNA and polyethylenimine (33) were mixed at a ratio of 1:3 (htRANKL or TNF-a, 200:600 mg) or 1:2 (scRANKL variants, 200:400 mg) in Opti-MEM (Life Technologies), incubated for 15 min at room temperature, and added directly to the cells. Cell culture medium was harvested 4 and 7 days after transfection, filtered through a 0.22-mm filter, and equilibrated by the addition of 0.1 volume of 10× PBS (Gibco) and 10 mM imidazole. The protein was captured on Ni-NTA Superflow resin (Qiagen) and washed with 10 mM imidazole in PBS. Protein was eluted in steps from 25 to 500 mM imidazole. Fractions containing purified protein were identified by Coomassie-stained SDS-PAGE. Protein-containing fractions were pooled and concentrated with a disposable YM30 Centricon (Millipore). All proteins were sterilefiltered for use in cell culture. Only lipopolysaccharide-free plastics and reagents were used for all purifications. 
SPR measurements
All SPR experiments were performed on a Biacore T100 (GE Healthcare) with CM5 sensor chips and HBS-EP buffer [10 mM Hepes (pH 7.4), 150 mM NaCl, 3 mM EDTA, and 0.05% (v/v) Surfactant P20]. To confirm receptor binding to scRANKL variants, 4000 RUs of wild-type scRANKL or variant scRANKL were coupled to individual lanes, leaving one reference flow cell uncoupled. Monomeric RANK (20 mM) was flowed over until saturation. Total RUs bound at equilibrium were calculated with BIAevaluation software. Experiments to determine kinetic affinity constants of RANKL variants for RANK or OPG were performed and analyzed as previously described (9) .
Generation of osteoclasts from primary BMMs
Long bones isolated from 8-week-old mice were flushed, and the marrow was subjected to red blood cell lysis. The remainder of the whole marrow was cultured on Petri dishes or bone powder as previously described (34) , maintained at 37°C and 6% CO 2 in a-minimum essential medium (a-MEM) containing 10% heat-inactivated fetal bovine serum, penicillin (100 U/ml), and streptomycin (100 mg/ml) (a-10 medium), supplemented with 1:10 CMG [conditioned medium supernatant containing recombinant M-CSF (macrophage colony-stimulating factor)] (35). Osteoclasts were differentiated in a-10 medium with 1:50 CMG and the relevant RANKL variant.
Detection of osteoclast formation
Cells were fixed in 4% paraformaldehyde in PBS for 15 min and stained for TRAP with a specific kit (Sigma). Additionally, osteoclasts were quantified by a solution assay of TRAP enzyme activity. Cells were fixed and lysed in 90 mM citrate buffer (pH 5.2), 80 mM sodium tartrate, and 0.1% Triton X-100 for 10 min at room temperature. Colorimetric nitrophenylphosphate (a substrate of TRAP) was added and visualized after 15 min by the addition of sodium hydroxide. Data were acquired with the 405-nM absorbance filter on a Bio-Rad plate reader. Because of the limited range of the TRAP solution assay, a more quantitative assessment of TRAP activity was performed with the fluorescent phosphatase substrate ELF-97 (Molecular Probes). Fixed cells were incubated with 100 mM ELF-97 in 90 mM citrate buffer (pH 4.8) and 80 mM sodium tartrate for 15 min at room temperature. The reaction was stopped by the addition of sodium hydroxide, and fluorescence was visualized with the 345/530 excitation/emission filter on a SpectraMax M2 plate reader.
MALS analysis
Purified RANKL proteins were applied to a Wyatt WTC-030S5 size exclusion column mounted on a Waters HPLC (high-performance liquid chromatography) system attached to a MALS device. The light detectors, a DAWN HELEOS II 18-angle light scattering detector and an Optilab T-rEX refractive index, were previously calibrated against monomeric bovine serum albumin (BSA). MALS was monitored during the experiments, and the resulting data were analyzed with associated software. For each experiment, 250 mg of sample was applied at a concentration of 1 mg/ml in running buffer [25 mM Hepes (pH 7.4), 150 mM NaCl, and 0.01% sodium azide] at 20°C and a flow rate of 0.5 ml/min.
Chemical cross-linking
Purified wild-type RANKL protein (500 ng) was incubated with varying concentrations (0 to 500 mM) of the chemical cross-linker bis-(sulfosuccinimidyl)-suberate (BS 3 , Pierce) in PBS at room temperature for 30 min, at which time the reaction was stopped by the addition of 10 mM tris-HCl (pH 7.0). Samples were boiled under reducing conditions and loaded onto SDS-PAGE gels (10%) alongside 500 ng of scRANKL protein. Bands were stained with the Coomassie derivative Imperial Protein Stain (Pierce) and visualized with the Odyssey scanner (Li-Cor).
Identification of RANKL mutants that did not bind to RANK
RANKL residues forming salt bridges or hydrogen bonds with RANK were targeted for site-directed mutagenesis with PISA software based on the RANK-RANKL co-crystal structure (9) . Loops at the RANK-RANKL binding interface were disrupted by amino acid insertion. Mutations were introduced into the expression construct pGEX-GST-RANKL by PCR with Phusion polymerase (New England BioLabs). The constructs were verified by nucleic acid sequencing. Escherichia coli strain BL21-CodonPlus(DE3)-RIL competent cells (Agilent Technologies) were transformed with the mutant RANKL-encoding constructs to generate proteins. Correctly folded soluble proteins were purified from cell lysates on glutathione Sepharose (8).
Biolayer interferometry
All BLI experiments were performed on an Octet RED System (ForteBio). GST-RANKL fusion proteins were biotinylated with NHS-PEG4-Biotin (Pierce) according to the manufacturer's protocol, and excess biotin was removed by desalting over Zeba Spin Columns (7-kD molecular mass cutoff, Pierce). Biotinylated proteins were adsorbed onto Super Streptavidin sensor pins (ForteBio). Binding of RANK-Fc or OPG-Fc was measured in HBS-EP containing 1% BSA. Because of the dimeric nature of Fc-tagged receptors, only apparent dissociation constant (K D ) values were observed.
Quantitative real-time PCR analysis
To quantitate the abundances of messenger RNAs for markers of osteoclast formation, total RNA was isolated from cultured cells with the Qiagen RNeasy miniprep kit according to the manufacturer's protocol. Equal amounts of RNA were used to perform reverse transcription with BioRad iScript, and quantitative real-time PCR analysis was performed with SsoFast EvaGreen qPCR kit (Bio-Rad) with a 7500 fast machine (ABI). Cyclophilin was used as the housekeeping control gene. Data were analyzed according to the DDC t method and expressed relative to a control containing no RANKL addition (labeled BMM). The primers used were as follows: cathepsin K (forward: 5′-ATGTGGGTGTTCAAGTTTCTGC-3′, reverse: 5′-CCACAAGATTCTGGGGACTC-3′); NFATc1 (forward: 5′-CCCGT-CACATTCTGGTCCAT-3′, reverse: 5′-CAAGTAACCGTGTAGCTGCA-CAA-3′); TRAP (forward: 5′-CAGCTCCCTAGAAGATGGATTCAT-3′, reverse: 5′-GTCAGGAGTGGGAGCCATATG-3′); b 3 (forward: 5′-TTCG-ACTACGGCCAGATGATT-3′, reverse: 5′-GGAGAAAGACAGGTCCAT-CAAGT-3′); and cyclophilin (forward: 5′-AGCATACAGGTCCTGGCATC-3′, reverse: 5′-TTCACCTTCCCAAAGACCAC-3′).
Western blotting
Cells were washed three times in ice-cold PBS and lysed with radioimmunoprecipitation assay buffer (Millipore) supplemented with protease and phosphatase inhibitor cocktail (Pierce). After 10 min of incubation on ice, cell lysates were cleared of debris by centrifugation for 15 min at 21,000g. Forty to 50 mg of protein was resolved by 10% SDS-PAGE, transferred onto polyvinylidene difluoride membranes, and incubated with primary antibody overnight. After extensive washing and incubation with near-infrared-labeled secondary antibody, membranes were visualized with the Odyssey scanner (Li-Cor). Primary antibodies to detect phosphorylated or total nuclear factor kB or p38 MAPK proteins were obtained from Cell Signaling Technology; antibody against actin was from Sigma; and fluorescently labeled secondary antibodies were obtained from Rockland.
YSD of RANKL and flow cyometric analysis of staining with monomeric RANK or OPG
The cDNA encoding WT-SM RANKL was subcloned into the pYD1 yeast display vector (Life Technologies) at the Nhe I and Xho I restriction sites to generate the yeast mating protein Aga2p fused to the RANKL N terminus and having a V5 epitope tag at the C terminus. EBY100 yeast cells were transformed with the pYD1-RANKL construct using the lithium acetate/ single-stranded DNA method as described previously (36) , and colonies were selected in tryptophan-deficient, glucose-based medium at 30°C. Display of RANKL protein was induced by inoculating into galactosebased selective medium and incubating at 30°C with shaking for 24 to 48 hours. Surface expression of RANKL was detected with a fluorescein isothiocyanate (FITC)-conjugated anti-V5 antibody (Invitrogen). After incubation with RANK-Fc or OPG-Fc for 10 min at room temperature and washing with ice-cold PBS, receptor binding was detected with an allophycocyanin (APC)-conjugated anti-human Fc antibody (Molecular Probes). All experiments were performed with LSR II or Canto II flow cytometers (BD Biosciences), and data were analyzed with the FlowJo software package (Tree Star Inc.). Alternatively, RANK-6xHis or OPG6xHis proteins were detected with APC-labeled anti-6xHis antibody (MBL International).
Generation of RANKL library and selection
Primers annealing immediately 5′ or 3′ to the cDNA sequence encoding RANKL in the pYD1 vector were designed and used in error-prone PCR amplification (GeneMorph II, Agilent). Lower and higher mutation rates were accomplished by manipulating the amount of starting template and the number of amplification cycles. The resulting product was further amplified with the high-fidelity Phusion polymerase (Finnzymes). Simultaneously, the pYD1 vector backbone was amplified with primers that extended outward from the regions surrounding RANKL-V5, leaving 24 base pairs of overlap between the vector backbone and the amplified mutant RANKL-V5 insert. These purified PCR products were used in the transformation of EBY100 cells according to established protocols (36) , which yielded a library of about 1 × 10 6 transformants. Selections were made with magnetic-assisted cell sorting (MACS, Miltenyi). About 1 × 10 7 cells were induced from either the low-or high-mutation rate libraries, and both were first sorted for the expression of the V5 C-terminal tag, which indicated proper folding of the full-length protein. This was performed by incubating the cells with FITC-labeled anti-V5 antibody and selecting cells with anti-FITC microbeads for cell separation. After growth of the selected clones, cells were again induced to display RANKL protein, incubated with OPG-Fc, and washed, and those clones that did not bind to OPG were collected as the flow-through on a Protein A magnetic bead column. These cells were then labeled with RANK-Fc, and this time, those clones that retained binding to the Protein A column were collected. After sorting, cells were allowed to multiply in selective medium, and this strategy was repeated twice to yield clones termed "LM3S" and "HM3S." About 200 individual colonies were isolated from the libraries and stained with OPGFc. Those clones with little to no detectable staining were then assessed for their ability to bind to RANK-Fc. DNA was extracted from the topscoring clones of interest with a yeast miniprep kit (Zymoprep) and used to transform chemically competent DH5a E. coli (Invitrogen) for sequencing. Individual point mutations were then added to the cDNA encoding RANKL by site-directed mutagenesis, and subsequent combinations were cloned in a similar fashion. A second round of error-prone PCR used the identical primers and protocol described earlier, but used as the starting template either of the F164Y/Q236H/F269Y or K194N/Q236H/ F269Y triple mutants. Clones were selected over three rounds of sorting with three sequentially lower amounts of monomeric RANK-6xHis and anti-6xHis microbeads. Finally, the resulting library was incubated with RANK-6xHis at room temperature for 10 min and then tested for the ability to outcompete the presence of unlabeled OPG at room temperature for 5 min. Residual RANK binding was detected with APClabeled anti-6xHis antibody. In the course of sorting, the K194E mutation was identified and used to replace the K194N mutation, which introduced a potential N-linked glycosylation site at the interface with RANK or OPG.
Assessment of cell viability with the MTT assay
Cells were seeded in 96-well plates in a-MEM alone, with wild-type htRANKL (200 ng/ml) alone or in combination with single-block, RANK high (2000 ng/ml), or with single-block, RANK high alone. After 3 days, a 1:10 dilution of MTT reagent [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Sigma-Aldrich] was added (final concentration of 0.5 mg/ml) to the culture medium and incubated at 37°C. After 3 hours, 150 ml of 0.04 N HCl in isopropanol was added to each well to stop the reaction, and MTT absorbance was determined at an optical density of 595 nm.
Coculture assays
Calvarial osteoblasts were isolated and expanded in number as previously described (37) . Briefly, osteoblasts were isolated from the calvaria of 3-day-old pups by 3 × 20-min treatments with collagenase. Cells were expanded in number in a-MEM medium and then were lifted and plated together with BMMs in a 96-well plate. Cells were cocultured in the presence of 10 nM 1,25-vitamin D 3 in a-MEM medium with the indicated concentrations of single-block, RANK high scRANKL. On day 7, cells were treated with 0.1% collagenase for 15 min to remove osteoblasts and then were fixed for TRAP staining.
Intraperitoneal injection of mice with RANKL
Eight-week-old female BALB/c mice were purchased from National Cancer Institute at Frederick, housed in the animal facility at Washington University School of Medicine, and maintained according to the guidelines set by the Association for Assessment and Accreditation of Laboratory Animal Care. All animal studies were approved by the Animal Studies Committee of Washington University School of Medicine. PBS, WT-SM RANKL (0.5 mg/kg), or WT-SM RANKL and singleblock, RANK high scRANKL (0.5 mg/kg) were injected intraperitoneally into the mice at 0, 24, and 48 hours, as previously described (38) . Mice were sacrificed 1.5 hours after the third injection, and serum was collected by cardiac puncture. Serum concentrations of CTx were determined by ELISA according to the manufacturer's protocol (Immunodiagnostics Systems).
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